Others have shown that combining the HER2/neu kinase inhibitor lapatinib with a HER2/neu antibody trastuzumab prolonged progression-free survival in patients with HER2/neu positive breast cancer.[40, 41]. Here, ERBB2 is linked to breast carcinoma.